A Phase II, Randomized, Open-label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First-line Therapy for Unresectable Pleural Mesothelioma in Chinese Participants
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pemetrexed (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms CheckMate 6DW
- Sponsors Bristol-Myers Squibb
- 24 Feb 2022 Status changed from not yet recruiting to recruiting.
- 01 Dec 2021 New trial record